two specific drugs from Isis's pipeline that have transformative potential both for patients and for Isis as a company. They are ISIS-TTRRX for thyretin-related amyloidosis and ISIS-SMNRX for spinal muscular atrophy. Both are for deadly, orphan indications, genetic disorders for which there are few to no treatments available, and both are expected to report proof of concept data within the coming year. To see what proof of concept is worth in such indications, take a look at what has happened to Sarepta (SRPT), another antisense RNA company, since July as it has announced more and more proof of concept data for its duchenne muscular dystrophy drug. Isis is a much larger company than Sarepta was, so it's not going to jump 10-fold on such news, but the potential gains are still substantial.